Beximco receives FDA nod for Baclofen

Beximco has received the Food and Drug Administration’s blessing for Baclofen in dosage strengths of 10 and 20 mg tablets.

The product is a muscle relaxant drug indicated for the treatment of muscle pain, spasms, and stiffness in people with multiple sclerosis or spinal cord injury or disease.

Baclofen had a market value of more than $110 million in 2020, according to IQVIA.

Nazmul Hassan, managing director of Beximco Pharmaceuticals, said, “We are pleased to have received FDA approval of Baclofen, a commonly prescribed medicine in the U.S., as we continue to leverage our core strengths in R&D and manufacturing to develop and deliver important generic products to patients. This approval strengthens our product offering in the U.S. and we look forward to the launch of generic Baclofen in due course.”